Viatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.
Follow VTRS
Viatris Inc. (VTRS) Revenue growth
Viatris Inc.'s revenue growth over the twelve months to 30 June 2026 was 4.40%, up 7.4 percentage points from fiscal 2025 (−2.98%). Over the past ten years it has ranged from −9.08% (fiscal 2022) to 49.7% (fiscal 2021); the current reading is higher than 45% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 10.0% and below the Healthcare sector median of 8.27%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | −2.98% | 1.48 |
| FY2024 | −4.46% | 0.68 |
| FY2023 | −5.14% | 3.94 |
| FY2022 | −9.08% | (58.81) |
| FY2021 | 49.7% | 45.86 |
| FY2020 | 3.87% | 3.29 |
| FY2019 | 0.58% | 4.56 |
| FY2018 | −3.98% | (11.48) |
| FY2017 | 7.50% | (9.97) |
| FY2016 | 17.5% | (4.68) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 4.88% | (3.19) |
| Mar 2026 | 8.07% | 3.10 |
| Dec 2025 | 4.97% | 4.74 |
| Sep 2025 | 0.23% | 5.88 |
| 42 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| NBIX Neurocrine Biosciences, Inc. compare | 34.4% |
| ELAN Elanco Animal Health Incorporated compare | 12.0% |
| VTRS Viatris Inc. | 4.40% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 4.13% |
| UTHR United Therapeutics Corporation compare | 2.49% |
| ZTS Zoetis Inc. compare | 1.58% |
| TAK Takeda Pharmaceutical Co. compare | 0.66% |
| RDY Dr. Reddy's Laboratories Ltd compare | −11.6% |
| HLN Haleon PLC Sponsored ADR compare | — |
| Drug Manufacturers Specialty & Generic industry median | 10.0% |
| Healthcare sector median | 8.27% |
| Market median | 7.41% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on VTRS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement